Journal
SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES
Volume 45, Issue 4, Pages 315-319Publisher
INFORMA HEALTHCARE
DOI: 10.3109/00365548.2012.732705
Keywords
Carbapenem resistance; Acinetobacter baumannii; bacteraemia; tigecycline
Categories
Ask authors/readers for more resources
Although tigecycline is considered one of the few therapeutic options for carbapenem-resistant Acinetobacter baumannii (CRAB) bacteraemia, its role in the treatment of CRAB bacteraemia remains unclear. We describe the clinical outcomes of 9 patients who received tigecycline for CRAB bacteraemia. Although all CRAB blood isolates were susceptible to tigecycline, 5 (56%) deaths were related to CRAB bacteraemia and 1 case of breakthrough CRAB bacteraemia was observed during tigecycline therapy. Clinical outcomes of tigecycline therapy may be poor in patients with tigecycline-susceptible CRAB bacteraemia, although multiple factors including delayed treatment could contribute to the poor outcomes.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available